Scott Soleimanpour, M.D. is an Associate Professor of Internal Medicine and Molecular and Integrative Physiology, Co-Director of the JDRF Center of Excellence at the University of Michigan, and Associate Director of the University of Michigan Caswell Diabetes Institute. Diagnosed with type 1 diabetes (T1D) in 1986, Dr. Soleimanpour is deeply invested in basic research focused on the genetic causes of beta cell failure in both T1D and type 2 diabetes (T2D). Dr. Soleimanpour attended Kent State University and the Northeast Ohio Medical University as part of a combined B.S./M.D. program. During his pre-doctoral and post-doctoral research training, Dr. Soleimanpour completed diabetes research fellowships in the Vanderbilt University/NIDDK medical scholars program, the Howard Hughes Medical Institute-National Institutes of Health (HHMI-NIH) Research Scholars program, and the William Osler Society of Fellows at the University of Pennsylvania before joining the faculty at Penn and moving to the University of Michigan in 2014. Among Dr. Soleimanpour’s key research contributions include studies focused on islet cell transplantation, the mitochondrial life cycle, and include seminal studies focused on control of pancreatic beta cell function by mitophagy. He has received awards and honors from the American Diabetes Association, Juvenile Diabetes Research Foundation, the American Society of Clinical Investigation, the Central Society for Clinical and Translational Research, the Alpha Omega Alpha National Medical Honors Society, and The Endocrine Society. The Soleimanpour Lab has pioneered the study of mitochondrial quality control in diabetes pathophysiology, and his lab continues to focus on how defects in the key mitophagy gene Clec16a lead to beta cell dysfunction in both T1D and T2D.